Literature DB >> 19603172

Management of the post chemotherapy subcentimeter residual mass: the case for observation.

Stephen D W Beck1, Richard S Foster.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19603172     DOI： 10.1007/s00345-009-0452-7

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  25 in total

1.  Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.

Authors:  S B Saxman; D Finch; R Gonin; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

2.  Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors.

Authors:  D J Debono; D K Heilman; L H Einhorn; J P Donohue
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

3.  Late relapse of testicular cancer.

Authors:  H R Terebelo; H G Taylor; A Brown; N Martin; F H Stutz; J Blom; L Geier
Journal:  J Clin Oncol       Date:  1983-09       Impact factor: 44.544

4.  A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer.

Authors:  R Ravi; R T Oliver; J Ong; D F Badenoch; C G Fowler; A M Paris; W F Hendry
Journal:  Br J Urol       Date:  1997-10

5.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

Review 6.  Late relapse of germ cell tumors after cisplatin-based chemotherapy.

Authors:  A Gerl; C Clemm; N Schmeller; M Hentrich; R Lamerz; W Wilmanns
Journal:  Ann Oncol       Date:  1997-01       Impact factor: 32.976

7.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz-Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

8.  Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?

Authors:  S D Fosså; H Qvist; A E Stenwig; H H Lien; S Ous; K E Giercksky
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

9.  Late relapse of testicular cancer.

Authors:  J Baniel; R S Foster; R Gonin; J E Messemer; J P Donohue; L H Einhorn
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.

Authors:  E W Steyerberg; H J Keizer; S D Fosså; D T Sleijfer; G C Toner; H Schraffordt Koops; P F Mulders; J E Messemer; K Ney; J P Donohue
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544
View more
  3 in total

1.  Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.

Authors:  Siamak Daneshmand; Hooman Djaladat; Craig Nichols
Journal:  Ther Adv Urol       Date:  2011-08

Review 2.  Management of Residual Mass in Germ Cell Tumors After Chemotherapy.

Authors:  Costantine Albany; Kenneth Kesler; Clint Cary
Journal:  Curr Oncol Rep       Date:  2019-01-21       Impact factor: 5.075

3.  Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.

Authors:  Eduardo de Paula Miranda; Daniel Kanda Abe; Adriano João Nesrallah; Sabrina Thalita dos Reis; Alexandre Crippa; Miguel Srougi; Marcos Francisco Dall'Oglio
Journal:  World J Surg Oncol       Date:  2012-09-28       Impact factor: 2.754
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.